Overview
The department of Oncology, founded in 1995, is a part of the national key discipline - Oncology. Under the joint guidance of Chinese and American experts, it has rapidly developed into a large-scale and comprehensive department of oncology in Zhejiang Province. At present, the monthly number of discharged patients has exceeded 1000, and the per capita cost of inpatients is the lowest among similar hospitals. It has 13 staff members with senior professional titles, including 4 doctoral supervisors and 6 master’s supervisors. In terms of members’ education backgrounds, there are 20 doctors and 14 masters. It has trained a large number of doctors, master students and advanced physicians, and has become an important base for medical oncology personnel training in Zhejiang Province. In recent years, clinical research in our department has developed rapidly as we have undertaken more than 200 international and domestic multi-center drug clinical studies with 2 PI assistants for clinical trials.
Since 1996, under the guidance of American experts, the department has held multidisciplinary diagnosis and treatment discussions (MDT) together with various other departments of the Cancer Center every Wednesday, and has stood at the forefront of the field of personalized treatment for cancer patients in China. It is also a strong and standardized gene testing center in Zhejiang Province to jointly detect dozens of molecular target genes with the Molecular Pathology Center of SRRSH, such as HER-2, EGFR, EML4-ALK, C-Kit, cMET, K-RAS, BRAF and MSI. With strong scientific research strength in the province, the department of Medical Oncology has undertaken 26 national Natural Science Foundation projects, 1 major special project of the provincial Science and Technology Department, and more than 30 provincial and ministerial science foundation projects, providing strong support for the application of translational oncology research in clinical practice.
Among the clinical studies carried out by the department, there are 8 lead studies and 6 single center phase I studies, among which the phase I study of recombinant human anti-EGFR monoclonal antibody Anmeimu injection carried out by Director Pan Hongming was approved as a major new drug creation special project of the Ministry of Science and Technology, and has led the national multi-center study of phase ⅰ B / ⅱ and ⅱ A colorectal cancer. As studies on "Combination" and "double antibody" have become the mainstream of anti-tumor research, the department of Medical Oncology is involved in more than 90 studies of ALK, EGFR, C-MET, VEGFR2, FGFR, MEK, ROS1/NTRK, VEGF, PARP, FGFR&FLT3 and other targets and pD-1, TGF-β, PD-L1, LAG3&PD-1 double antibody, PD-L1&CTLA-4 double antibody, PD-1&PD-L1 double antibody, and PD-L1&CTLA-4 double antibody. It has also participated in the research of several revolutionary breast cancer treatment drugs such as Sacituzumab Govitecan, Trastuzumab Deruxtecan (T-DXD), SAR439859, Tucatinib, and Palbociclib, the world's first approved CDK4/6 kinase inhibitor. The egFR-targeted drug Amivantamab (JNJ-6372, a dual target monoclonal antibody of EGFR and MET) in lung cancer has been granted the Breakthrough Therapy Certification on the FDA's website. The department of Medical Oncology has participated in a number of studies of anti-cancer drugs that have been recognized as breakthrough therapeutic drugs by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration (now National Medical Products Administration, NMPA), including CAR T therapy by Nanjing Legend, DS-8201A, Siorone capsules by Shenzhen Microchip Biotechnology Co., Ltd., Carerizumab and famitinib malate capsules by Hengrui Pharmaceutical, and YY-20394 tablets by Shanghai Maya Lai Pharmaceutical Co., Ltd.
Our department is one of the earliest units to carry out radiofrequency ablation for tumors in China, thus accumulating rich experience in radiofrequency ablation for tumors in the lung and liver near the top of the diaphragm. Zhejiang Science and Technology Department’s major scientific research project "based on nanomaterial technology development of new radiofrequency therapy needle and its application in the treatment of lung tumor" has made significant progress. Vice President Pan Hongming presided over the formulation of Chinese Tumor Nutritional Therapy Expert Consensus and Zhejiang Province Radiofrequency Ablation Technical Treatment Standards. The department is recognized as the quality control center of Tumor radiofrequency ablation in Zhejiang Province, and the first batch of the "Standardized Demonstration Ward for the Treatment of Cancer Pain" with high scores authorized by the National Health Commission. On September 20, 2012, the on-site experience exchange meeting of the "Standardized Demonstration Ward for the Treatment of Cancer Pain" organized by the National Health Commission was held in our hospital. Leaders and experts from more than 90 grade A hospitals in China came to our hospital for on-site observation. In 2018, the department hosted the third Annual Meeting of the Targeted Therapy Committee of Chinese Anti-Cancer Society. From 2018 to 2021, it hosted the first to the fourth China Cancer Nutrition and Comprehensive Therapy Conference for four consecutive years.
Academic standing：
Zhejiang Precision Diagnosis Center
Zhejiang province cancer pain standardized treatment demonstration ward
Zhejiang Tumor Targeted Therapy Technical Guidance Center
Resident Training Base of the National Health Commission
Chairman Unit of China Tumor Nutrition Therapy Expert Committee
Nominated Chairman Unit of the Targeted Therapy Committee of Chinese Anti-cancer Society
Diagnosis and treatment scope
Chemotherapy, immunotherapy and molecular targeted drug therapy for various advanced solid tumors, especially lung cancer, esophageal cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer, ovarian cancer, lymphoma, pancreatic cancer, endometrial cancer, cervical cancer, malignant melanoma, neuroendocrine tumor, and malignant tumor of unknown origin
Radiofrequency ablation for primary and metastatic lung cancer and liver cancer
Nutritional treatment of cancer patients, standardized treatment of cancer pain, and radiofrequency ablation therapy
Multi-center drug clinical research at home and abroad
Medical characteristics
1. Minimally invasive treatment of primary and metastatic liver cancer and lung cancer (radiofrequency ablation)
2. Early diagnosis, screening and prevention of malignant tumors
3. Chemotherapy, immunotherapy and molecular targeted therapy for advanced breast cancer; Perioperative management of breast cancer
4. Chemotherapy, immunotherapy and molecular targeted therapy for advanced lung cancer
5. Individualized comprehensive treatment of advanced gastric cancer; Perioperative treatment of gastric cancer
6. Individualized comprehensive treatment of advanced colorectal cancer; Perioperative treatment of colorectal cancer
7. Individualized comprehensive treatment of advanced liver cancer
8. Multidisciplinary diagnosis and treatment of tumors of unknown origin
9. Individualized treatment of advanced cancer pain
10. Nutritional therapy for patients with advanced tumors
11. Multi-center clinical studies of anti-tumor drugs at home and abroad
1. Focusing on "minimally invasive" and individualized treatment, the department aims to become a domestic specialty for the individualized treatment of solid tumors. Minimally invasive technology and individualized treatment are fully applied in various fields of solid tumor treatment, including lung cancer, breast cancer, stomach cancer, liver cancer, colorectal cancer, pancreatic cancer, etc. Our department is one of the earliest units to carry out radiofrequency ablation for tumors in China, thus accumulating rich experience in radiofrequency ablation for tumors in the lung and the liver or near the top of the diaphragm, etc. At present, it is the quality control center of Radiofrequency ablation in Zhejiang Province.
2. The department has cooperated with the Department of Pathology of our hospital to carry out gene diagnosis projects of more than 20 molecular targets, such as HER-2, EGFR, EML4-ALK, C-Kit, cMET, K-RAS, BRAF and MSI, and held multidisciplinary diagnosis and Treatment discussion (MDT) jointly with various departments of the Tumor Center of SRRSH every Wednesday. In the field of personalized treatment for cancer patients, the department stands at the forefront in China.
3. The department has led or participated in more than 200 international multi-center clinical trials of anticancer drugs, many of which were recognized as breakthrough therapy drugs by the Drug Review Center (CDE) of the State Food and Drug Administration (now National Medical Products Administration, NMPA).
4. With strong scientific research strength in the province, the department of Medical Oncology has undertaken 26 national Natural Science Foundation projects, 1 major special project of the provincial Science and Technology Department, and more than 30 provincial and ministerial science foundation projects, etc., providing strong support for the application of translational oncology research in clinical practice.
5. The department has promoted standardized cancer treatment. It is the first batch of "Standardized Demonstration Ward for Cancer Pain Treatment" recognized by the National Health Commission.
6. The department presided over the formulation of Expert Consensus on Nutritional Support and Treatment for Patients with Malignant Tumor in China.